News

A panel of United Kingdom-based experts has defined a set of practical considerations to manage motor fluctuations and wearing-off in Parkinson’s disease patients. Based on practical clinical experience, the guidelines were outlined in “Noninvasive options for ‘wearing-off’ in Parkinson’s disease: a clinical consensus from a panel of…

Approximately 1.2 million people in the United States are predicted to have Parkinson’s disease by the year 2030, according to the results of a large-scale study. This represents a projected increase by about 1.8 times in Parkinson’s prevalence since 2010, highlighting the need for optimized care and treatment strategies for this…

Sustained release formulation of pramipexole (Mirapex, Boehringer Ingelheim) outperforms its immediate release alternative to treat sleep disturbances in advanced Parkinson’s patients, a new study suggests. The research, “Comparison of nocturnal symptoms in advanced Parkinson’s disease patients with sleep disturbances: pramipexole sustained release versus immediate release formulations,” was…

Prana Biotechnology’s investigational compound PBT434 prevented neuronal loss and improved motor function in an animal model of multiple system atrophy (MSA), a condition that shares many of Parkinson’s motor symptoms, according to preclinical data. MSA is a progressive disorder affecting both involuntary functions, such as blood pressure,…

Researchers have analyzed the three-dimensional toxic form of the protein alpha-synuclein, which is directly involved in Parkinson’s disease. The findings are now challenging previous knowledge investigators had of this disease. Parkinson’s disease is a progressive neurodegenrative disorder that belongs to the class of synucleopathies. In these type of diseases,…

Neupro patches (rotigotine) have been approved in China for treating symptoms of early-stage idiopathic (of unknown cause) Parkinson’s disease as a stand-alone therapy or in combination with levodopa. Patients may benefit from this treatment strategy over the course of the disease, through to late stages, when levodopa’s benefit wears off or becomes…

Herantis Pharma is launching a development program for non-invasive cerebral dopamine neurotrophic factor (CDNF) as a treatment candidate for patients with Parkinson’s disease, the company recently announced. Currently, the investigational treatment needs to be administered directly into the brain using an implanted delivery system suited for Parkinson’s…

Xeomin (incobotulinumtoxinA) has been approved by the U.S. Food and Drug Administration to treat adults with chronic sialorrhea, or excessive drooling, a condition often experienced by Parkinson’s disease patients. Merz Neurosciences, a division of Merz North America, announced that its supplemental biologics license application for Xeomin…

Canadian researchers have gained new insight into the activation of a protein that plays an important role in the genetic form of Parkinson’s disease. Findings were published in the study, “Mechanism of parkin activation by phosphorylation,” published in Nature Structural & Molecular Biology. Parkinson’s disease is a neurodegenerative…

New research projects focused on better ways to monitor and treat Parkinson’s disease were awarded funding recently by the Michael J. Fox Foundation (MJFF). From more than 200 funding proposals submitted to its 2018 spring funding program, 39 projects were funded. Selected projects primarily come from the United States…